TNSN03051A1 - Derives d'ethers utiles comme inhibiteurs d'isozymes pde4. - Google Patents
Derives d'ethers utiles comme inhibiteurs d'isozymes pde4.Info
- Publication number
- TNSN03051A1 TNSN03051A1 TNPCT/IB2001/002726A TNSN03051A TNSN03051A1 TN SN03051 A1 TNSN03051 A1 TN SN03051A1 TN SN03051 A TNSN03051 A TN SN03051A TN SN03051 A1 TNSN03051 A1 TN SN03051A1
- Authority
- TN
- Tunisia
- Prior art keywords
- alkyl
- equal
- group
- ether derivatives
- derivatives useful
- Prior art date
Links
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 title 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 title 1
- 108010044467 Isoenzymes Proteins 0.000 title 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000003979 eosinophil Anatomy 0.000 abstract 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 125000003003 spiro group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composés utiles comme inhibiteurs de PDE4 dans le traitement de maladies régulées par l'activation et la dégranulation des cellules eosinophiles, notamment de l'asthme, de la bronchite chronique et d'une maladie pulmonaire obstructive chronique, de formule (I) dans laquelle j est égal à 0 ou 1 ; sous reserve que , lorsque j est égal à 0, n soit égal à 2; k est égal à 0 ou 1; m est égal à 1, 2 ou 3; n est égal à 1 ou 2 ; w 1 et w2 représentent des groupes -O - ; -S (=O)t -, dans lequel t est egal à 0, 1 ou 2; ou -N (R3) - ; y représente un groupe C (R1a) -, ou - (N - (0)k)- dans lequelk est égal à 0 ou 1; R1 a représente un groupe H ; - F ; -CI; -CN; -NO2; - alkyle en C1 à C4 ; - alcynyle en C2 à C4; -fluor-alkyle en C1 à C4; - fluoralkoxy en C1 à C3; - OR16 ou - C (=o) NR22 a R 22b; RA et RB représentent des groupes - H ; - F , - CF3; - alkyle en C1 à C4; - cycloalkyle en C3 à C7; phényle ou benzyle substitué avec 0 à 3 substituants R10; ou bien RA et RB sont pris conjointement pour former un groupement spiro de formule (ia) dans laquelle r et s ont des valeurs de 0 à 4 , sous réserve que la somme r+s soit supérieure ou égale à 1 mais non supérieure à 5; et XA représente un groupe -CH2-, -CHF,-CF2,-NR15-, -O - ou - S (=O)t -, dans lequel t est égal à 0 ou 1; Rc et Rd sont identiques à RA et RB , sauf qu'un d'entre eux doit représenter -H ; R1 et R2 représentent des groupes -H , -F, -C1, -CN, - NO2, alkyle en C1 à C4, alcynyle en C2 à C4, fluoralkyle en C1 à C3, -OR16 ou -C (=O) NR22aR22b; R3 représente -H, -alkyle en C1 à C3, phényle , benzyle ou -OR16; R4,R5 et R6, D, J1 et J2 répondent aux définitions figurant dans la présente demande.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26530401P | 2001-01-31 | 2001-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN03051A1 true TNSN03051A1 (fr) | 2005-12-23 |
Family
ID=23009905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNPCT/IB2001/002726A TNSN03051A1 (fr) | 2001-01-31 | 2003-07-08 | Derives d'ethers utiles comme inhibiteurs d'isozymes pde4. |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US6828333B2 (fr) |
| EP (1) | EP1373258B1 (fr) |
| JP (1) | JP2004518689A (fr) |
| KR (1) | KR20030070150A (fr) |
| CN (1) | CN1527830A (fr) |
| AP (1) | AP2002002415A0 (fr) |
| AR (1) | AR032522A1 (fr) |
| AT (1) | ATE305467T1 (fr) |
| BG (1) | BG107960A (fr) |
| BR (1) | BR0116845A (fr) |
| CA (1) | CA2436544A1 (fr) |
| CR (1) | CR7043A (fr) |
| CZ (1) | CZ20031902A3 (fr) |
| DE (1) | DE60113731T2 (fr) |
| EA (1) | EA200300652A1 (fr) |
| EE (1) | EE200300361A (fr) |
| ES (1) | ES2248231T3 (fr) |
| GT (1) | GT200200012A (fr) |
| HU (1) | HUP0302891A2 (fr) |
| IL (1) | IL156460A0 (fr) |
| IS (1) | IS6847A (fr) |
| MA (1) | MA26984A1 (fr) |
| MX (1) | MXPA03006885A (fr) |
| NO (1) | NO20033399L (fr) |
| NZ (1) | NZ526531A (fr) |
| OA (1) | OA12541A (fr) |
| PA (1) | PA8537901A1 (fr) |
| PE (1) | PE20020846A1 (fr) |
| PL (1) | PL364910A1 (fr) |
| SK (1) | SK8942003A3 (fr) |
| SV (1) | SV2003000861A (fr) |
| TN (1) | TNSN03051A1 (fr) |
| WO (1) | WO2002060896A1 (fr) |
| ZA (1) | ZA200304893B (fr) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2248231T3 (es) * | 2001-01-31 | 2006-03-16 | Pfizer Products Inc. | Derivados de eteres utiles como inhibidores de las isozimas pde4. |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| US6777432B1 (en) * | 2001-09-04 | 2004-08-17 | Darwin Molecular Corporation | Pharmaceutical uses and synthesis of nicotinamides |
| PL210463B1 (pl) * | 2001-09-19 | 2012-01-31 | Nycomed Gmbh | Zastosowanie kombinacji roflumilastu z diklofenakiem w leczeniu zapalnych chorób stawów |
| US20050158371A1 (en) * | 2002-02-12 | 2005-07-21 | Sumitomo Pharmaceuticals Co., Ltd. | Novel external agent |
| ATE457716T1 (de) | 2002-12-30 | 2010-03-15 | Angiotech Int Ag | Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung |
| US20060083714A1 (en) * | 2003-01-27 | 2006-04-20 | Warner James M | Combination of a pde iv inhibitor and a tnf-alpha antagonist |
| TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| US20050186276A1 (en) * | 2003-07-17 | 2005-08-25 | Pfizer Inc | Pharmaceutical formulations |
| GB0317516D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
| GB0317471D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Novel compounds |
| US7132435B2 (en) | 2003-07-25 | 2006-11-07 | Pfizer Inc. | Compounds |
| US7153870B2 (en) | 2003-07-25 | 2006-12-26 | Pfizer Inc. | Nicotinamide derivatives useful as PDE4 inhibitors |
| GB0317484D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| US20050187278A1 (en) * | 2003-08-28 | 2005-08-25 | Pharmacia Corporation | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors |
| JP2007504201A (ja) * | 2003-09-05 | 2007-03-01 | アルタナ ファルマ アクチエンゲゼルシャフト | 真性糖尿病の治療のためのｐｄｅ４阻害剤の使用 |
| WO2005080320A1 (fr) | 2004-02-13 | 2005-09-01 | Warner-Lambert Company Llc | Modulateurs du recepteur d'androgene |
| EP1737813A1 (fr) * | 2004-04-13 | 2007-01-03 | Warner-Lambert Company LLC | Modulateurs d'androgenes |
| EP1740533A1 (fr) | 2004-04-22 | 2007-01-10 | Warner-Lambert Company LLC | Modulateurs des androgenes |
| WO2006006065A1 (fr) | 2004-07-08 | 2006-01-19 | Warner-Lambert Company Llc | Modulateurs d'androgenes |
| MX2007010560A (es) * | 2005-03-08 | 2008-02-21 | Nycomed Gmbh | Roflumilast para el tratamiento de diabetes mellitus. |
| WO2006094942A1 (fr) * | 2005-03-08 | 2006-09-14 | Nycomed Gmbh | Roflumilast pour le traitement du diabète sucré |
| NZ561746A (en) * | 2005-04-19 | 2011-09-30 | Nycomed Gmbh | Roflumilast for the treatment of pulmonary hypertension |
| TW200724139A (en) | 2005-05-05 | 2007-07-01 | Warner Lambert Co | Androgen modulators |
| EP2258359A3 (fr) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline |
| EP1928437A2 (fr) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenese par modulation du recepteur muscarinique |
| JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Ｐｄｅ阻害による神経新生の調節 |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| TWI385169B (zh) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
| US20070225217A1 (en) | 2005-11-09 | 2007-09-27 | Combinatorx, Incorporated | Methods, compositions, and kits for the treatment of medical conditions |
| WO2007075801A2 (fr) * | 2005-12-20 | 2007-07-05 | Tika Läkemedel Ab | Méthode et système d'administration de corticostéroïdes présentant un meilleur profil pharmacocinétique |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2021000A2 (fr) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenèse par modulation de l'angiotensine |
| MX2008014320A (es) | 2006-05-09 | 2009-03-25 | Braincells Inc | Neurogenesis mediada por el receptor de 5-hidroxitriptamina. |
| MX2009002496A (es) | 2006-09-08 | 2009-07-10 | Braincells Inc | Combinaciones que contienen un derivado de 4-acilaminopiridina. |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
| US8569229B2 (en) * | 2008-02-07 | 2013-10-29 | The Children's Hospital Of Philadelphia | Compositions and methods which modulate G-protein signaling for the treatment of inflammatory disorders such as asthma and allergic conjunctivitis |
| EP2324005A1 (fr) * | 2008-08-05 | 2011-05-25 | The Ohio State University Research Foundation | Nouveaux composés phénoliques de méthylènedioxy et leur utilisation pour traiter une maladie |
| WO2010099217A1 (fr) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine |
| US20100280031A1 (en) * | 2009-04-30 | 2010-11-04 | Paul David | Lipid formulation of apoptosis promoter |
| US8728516B2 (en) * | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| AR076590A1 (es) * | 2009-05-19 | 2011-06-22 | Vivia Biotech Sl | Metodos para proveer pruebas medicinales personalizada ex vivo para neoplasmas hematologicos |
| TWI540132B (zh) * | 2009-06-08 | 2016-07-01 | 亞培公司 | Ｂｃｌ-２族群抑制劑之口服醫藥劑型 |
| TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| US8697691B2 (en) * | 2009-12-21 | 2014-04-15 | Vanderbilt University | Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective M1 agonists and methods of making and using same |
| JP5779591B2 (ja) * | 2009-12-22 | 2015-09-16 | アッヴィ・インコーポレイテッド | Ａｂｔ−２６３カプセル剤 |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| US9452173B2 (en) | 2013-01-31 | 2016-09-27 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| US9433680B2 (en) | 2013-01-31 | 2016-09-06 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| US8778365B1 (en) | 2013-01-31 | 2014-07-15 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| US9446131B2 (en) | 2013-01-31 | 2016-09-20 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| WO2015041809A2 (fr) | 2013-08-26 | 2015-03-26 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Reprogrammation cellulaire par petites molécules pour générer des cellules neuronales |
| CN108299418A (zh) * | 2017-09-14 | 2018-07-20 | 刘双伟 | 一种抗过敏和哮喘的噻唑基烟酰胺类化合物的合成方法 |
| EP4073025B1 (fr) * | 2019-12-13 | 2024-03-27 | Inspirna, Inc. | Sels métalliques et leurs utilisations |
| IT201900025126A1 (it) * | 2019-12-20 | 2021-06-20 | Sildeha Swiss S A | Uso di derivati dell’acido ialuronico nella rigenerazione dei tessuti ossei e cartilaginei |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| KR102404883B1 (ko) | 2020-11-30 | 2022-06-07 | (주)이노보테라퓨틱스 | 벤즈브로마론을 포함하는 켈로이드 또는 비대흉터 예방 또는 치료용 약학 조성물 |
| CN114907315B (zh) * | 2022-05-17 | 2023-09-12 | 重庆医科大学 | Selitrectinib中间体的合成方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2140772A5 (en) | 1971-06-07 | 1973-01-19 | Aries Robert | Phenoxynicotinoylaminophenols - analgesics tranquillisers antipyretics, anti-inflammatories and antirheumatics |
| US4270946A (en) * | 1979-10-01 | 1981-06-02 | Stauffer Chemical Company | N-Aryl,2-phenoxy nicotinamide compounds and the herbicidal use thereof |
| US4692185A (en) * | 1986-01-13 | 1987-09-08 | Stauffer Chemical Company | N-(ortho-substituted) benzyl, 3-trifluoromethylphenoxy nicotinamides as herbicides |
| US4861891A (en) | 1988-08-31 | 1989-08-29 | Pfizer Inc. | Antidepressant N-substituted nicotinamide compounds |
| ATE174343T1 (de) | 1991-02-27 | 1998-12-15 | Lacer Sa | Antihypertensive n-(alpha-substituiertes pyridyl)-carbonyldipeptide |
| US5602438A (en) * | 1991-02-28 | 1997-02-11 | Robert Bosch Gmbh | Roll commutator for electric motors and dynamos, and method of manufacturing it |
| DE4200323A1 (de) | 1992-01-09 | 1993-07-15 | Bayer Ag | Herbizide und pflanzennematizide mittel auf basis von mercaptonicotinsaeurederivaten |
| AU677776B2 (en) | 1992-04-02 | 1997-05-08 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
| JPH08511805A (ja) | 1993-06-18 | 1996-12-10 | スミスクライン・ビーチャム・コーポレイション | 化合物 |
| JP3406689B2 (ja) | 1994-03-15 | 2003-05-12 | 株式会社大塚製薬工場 | ナフチリジン及びピリドピラジン誘導体 |
| US5618027A (en) * | 1994-07-20 | 1997-04-08 | Nevrekar; Venkatesh R. | Gate valve |
| WO1996019990A1 (fr) | 1994-12-23 | 1996-07-04 | Smithkline Beecham Corporation | Monomeres 4,4-(disubstitues)cyclohexan-1-carboxylate et composes correspondants |
| TW429148B (en) * | 1995-10-27 | 2001-04-11 | Pfizer | Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases |
| EP0796619A1 (fr) * | 1996-03-21 | 1997-09-24 | Merrell Pharmaceuticals Inc. | Utilisation de (+)-alpha-(2,3-diméthoxyphényle)-1-(2-(4-fluorophényle)éthyle)-4-pipéridineméthanol pour le traitement des troubles dépressifs et bipolaires |
| FR2754178B1 (fr) * | 1996-10-04 | 2002-08-23 | Adir | Utilisation de la sulbutiamine pour l'obtention de compositions pharmaceutiques utiles dans le traitement de certains troubles psychomoteurs et psycho-intellectuels |
| GB9622386D0 (en) | 1996-10-28 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| US5922557A (en) | 1997-01-09 | 1999-07-13 | Merck & Co., Inc. | System for stably expressing a high-affinity camp phosphodiesterase and use thereof |
| CN1254335A (zh) | 1997-04-04 | 2000-05-24 | 辉瑞产品公司 | 烟酰胺衍生物 |
| GB9715584D0 (en) * | 1997-07-23 | 1997-10-01 | Eisai Co Ltd | Compounds |
| UA67753C2 (uk) | 1997-10-10 | 2004-07-15 | Смітклайн Бічам Корпорейшн | Спосіб отримання заміщених 4-феніл-4-ціанциклогексанових кислот |
| AR015966A1 (es) | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
| MA24682A1 (fr) | 1997-10-23 | 1999-07-01 | Smithkline Beecham Corp | Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant |
| TR200201880T2 (tr) * | 2000-01-31 | 2002-11-21 | Pfizer Products Inc. | PDE4 izozimerlerinin seçici önleyicileri olarak faydalı nikotinamit benzobağlı-heterosiklil türevleri |
| GEP20043385B (en) * | 2000-01-31 | 2004-04-13 | Pfizer Prod Inc | Pyrimidine Carboxamides Useful as Inhibitors of PDE4 Isozymes, Pharmaceutical Compositions Containing the Same |
| ES2248231T3 (es) * | 2001-01-31 | 2006-03-16 | Pfizer Products Inc. | Derivados de eteres utiles como inhibidores de las isozimas pde4. |
-
2001
- 2001-12-24 ES ES01273558T patent/ES2248231T3/es not_active Expired - Lifetime
- 2001-12-24 AT AT01273558T patent/ATE305467T1/de not_active IP Right Cessation
- 2001-12-24 IL IL15646001A patent/IL156460A0/xx unknown
- 2001-12-24 EE EEP200300361A patent/EE200300361A/xx unknown
- 2001-12-24 BR BR0116845-2A patent/BR0116845A/pt not_active IP Right Cessation
- 2001-12-24 KR KR10-2003-7010088A patent/KR20030070150A/ko not_active Application Discontinuation
- 2001-12-24 CN CNA018230989A patent/CN1527830A/zh active Pending
- 2001-12-24 PL PL01364910A patent/PL364910A1/xx not_active Application Discontinuation
- 2001-12-24 EP EP01273558A patent/EP1373258B1/fr not_active Expired - Lifetime
- 2001-12-24 CA CA002436544A patent/CA2436544A1/fr not_active Abandoned
- 2001-12-24 CZ CZ20031902A patent/CZ20031902A3/cs unknown
- 2001-12-24 NZ NZ526531A patent/NZ526531A/en unknown
- 2001-12-24 SK SK8942003A patent/SK8942003A3/sk unknown
- 2001-12-24 WO PCT/IB2001/002726 patent/WO2002060896A1/fr active IP Right Grant
- 2001-12-24 DE DE60113731T patent/DE60113731T2/de not_active Expired - Fee Related
- 2001-12-24 EA EA200300652A patent/EA200300652A1/ru unknown
- 2001-12-24 OA OA1200300176A patent/OA12541A/en unknown
- 2001-12-24 JP JP2002561464A patent/JP2004518689A/ja active Pending
- 2001-12-24 MX MXPA03006885A patent/MXPA03006885A/es active IP Right Grant
- 2001-12-24 HU HU0302891A patent/HUP0302891A2/hu unknown
-
2002
- 2002-01-28 GT GT200200012A patent/GT200200012A/es unknown
- 2002-01-29 PA PA20028537901A patent/PA8537901A1/es unknown
- 2002-01-29 AR ARP020100307A patent/AR032522A1/es unknown
- 2002-01-30 PE PE2002000070A patent/PE20020846A1/es not_active Application Discontinuation
- 2002-01-30 SV SV2002000861A patent/SV2003000861A/es not_active Application Discontinuation
- 2002-01-31 US US10/066,503 patent/US6828333B2/en not_active Expired - Fee Related
- 2002-01-31 AP APAP/P/2002/002415A patent/AP2002002415A0/en unknown
-
2003
- 2003-06-16 IS IS6847A patent/IS6847A/is unknown
- 2003-06-24 ZA ZA200304893A patent/ZA200304893B/xx unknown
- 2003-07-01 BG BG107960A patent/BG107960A/xx unknown
- 2003-07-08 TN TNPCT/IB2001/002726A patent/TNSN03051A1/fr unknown
- 2003-07-21 MA MA27242A patent/MA26984A1/fr unknown
- 2003-07-30 CR CR7043A patent/CR7043A/es unknown
- 2003-07-30 NO NO20033399A patent/NO20033399L/no not_active Application Discontinuation
-
2004
- 2004-08-13 US US10/918,820 patent/US7183293B2/en not_active Expired - Fee Related
-
2007
- 2007-01-30 US US11/668,915 patent/US20070161681A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN03051A1 (fr) | Derives d'ethers utiles comme inhibiteurs d'isozymes pde4. | |
| MA26983A1 (fr) | Derives biaryliques de nicotinamide utiles comme inhibiteurs d'iso-enzymes pde4 | |
| MA26985A1 (fr) | Derives d'amides de thiazolyl-,oxazolyl-pyrrolyl-et imidazolyl-acides utiles comme inhibiteurs d'isozymes pde4 | |
| PE20040937A1 (es) | Derivados de piridazin-3(2h)-ona como inhibidores de fosfodiesterasa-4 (pde 4) | |
| DE602004024093D1 (de) | 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe | |
| HUP0302922A2 (hu) | Sejtburjánzást gátló hatású imidazolo-5-il-2-anilino-pirimidinek és ezeket tartalmazó gyógyszerkészítmények | |
| MA27713A1 (fr) | Composes aminoheteroaryliques servant d'inhibiteurs de proteine-kinases | |
| MA33502B1 (fr) | Composés pyrazolopyrimidine inhibiteurs des jak et procédés | |
| MA28279A1 (fr) | Derives d'indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2 | |
| AR057062A1 (es) | Moduladores de aminoquinolina y aminoquinazolina quinasa | |
| TW200745058A (en) | MMP-13 selective inhibitors | |
| HUP0002510A2 (hu) | Tetrazolszármazékok és a vegyületeket tartalmazó gyógyászati készítmények | |
| MY140872A (en) | 5,7-diaminopyrazolo[4,3-d]pyrimidines with pde-5 inhibitory activity, compositions containing such derivatives and the use of such derivatives in the treatment of hypertension and other disorders | |
| CR9053A (es) | Uso de 2-fenil-1,2-etanodiol-(id) carbamatos para tratar epileptogenesis y epilepsia | |
| MA30756B1 (fr) | Derives de cinnamoyl-piperazine et leur utilisation comme antagonistes par-1 | |
| TN2009000160A1 (fr) | Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoides | |
| NO20080877L (no) | Fremgangsmater for behandling av substansrelaterte forstyrrelser | |
| EP1599201A4 (fr) | Modulateurs selectifs de recepteurs de glucocorticoides non steroidaux | |
| HRP20090112T3 (en) | 2- (1h-indolylsulfanyl) -aryl amine derivatives for use in the treatment of affective disorders, pain, adhd and stress urinary incontinence | |
| ATE480239T1 (de) | Angiogeneseinhibitoren | |
| NO20072444L (no) | Karbamatforbindelser for anvendelse i behandling av neurodegenerative forstyrrelser | |
| TW200607808A (en) | Pyrido-pyrimidine derivatives, preparation thereof and application thereof | |
| CA2508194A1 (fr) | Utilisation d'ibudilast en tant qu'inhibiteur d'une phosphodiesterase 10a | |
| MX2009004553A (es) | Metodos para el tratamiento de trastornos cocleares y vestibulares. | |
| CO6241194A2 (es) | Derivados de benzimidazol y su uso para la modulacion del complejo receptor de gabaa |